According to the Department of Health and Human Services, approximately 28,600 Americans die every year from overdoses involving opioid-based painkillers. The opioid epidemic is costing the country $55 billion a year. Where available, medical cannabis is already being used to treat a variety of the same conditions painkillers are used for including chronic pain.
Tetra Bio-Pharma’s PPP001 is the first smokeable cannabis drug product being developed for the treatment of pain in late-stage cancer patients. If approved by the FDA, the company’s PPP001 will be sold as a titanium pipe and blister pack containing drug pellets with
According to a new study published on May 25, 2017, in The New England Journal of Medicine, the oral administration of CBD (cannabidiol) reduces seizure frequency in children with intractable epilepsy.
It’s fairly common knowledge that regular use of THC, the chemical in marijuana which causes intoxication, results in a buildup of tolerance to its effects. In other words, the longer you use THC, the more you need to get the same effects. Does THC-free CBD oil from hemp cause this same effect? According to scientific research, not only does regular use of CBD oil not produce a tolerance buildup, it may result in what is known as reverse tolerance in which less of the compound is needed to produce the same effect.
Results are in from a Phase 2 clinical trial of a CBD-based gel formulated to treat a congenital condition known as Fragile-X syndrome, a condition which causes mild to severe intellectual disability. The experimental drug known as ZYN002 is being developed by Zynerba Pharmaceuticals.
Data collected in the study suggests that one year of treatment with the topically applied drug can provide sustained benefit to young patients suffering from the condition.
As CBD Journal reported back in June, the FDA has approved the use of a CBD-based drug called Epidiolex for the treatment of two of the hardest-to-treat forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome. According to a story in the New York Times, makers of the drug, British-based GW Pharmaceuticals, says the drug will cost roughly $32,500 per year.